Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.39 |
| ▸ | RELA | Q04206 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16565475 | 0.82 | AHR (0.54) | JAK2JAK3PTK2PDE10AKDM4E | |
| SCHEMBL23840318 | 0.80 | JAK2 (0.40) | JAK2JAK3PTK2KDM4EALDH1A1 | |
| SCHEMBL23642651 | 0.80 | CYP11B2 (0.47) | JAK2JAK3PTK2PDE10AKDM4E | |
| SCHEMBL2640521 | 0.80 | JAK2 (0.54) | JAK2JAK3PTK2PDE10AKDM4E | |
| SCHEMBL20605113 | 0.80 | JAK2 (0.44) | JAK2JAK3PTK2PDE10AKDM4E | |
| SCHEMBL13112326 | 0.80 | JAK2 (0.44) | JAK2JAK3PTK2PDE10AKDM4E | |
| SCHEMBL23030108 | 0.77 | JAK2 (0.56) | JAK2JAK3PTK2PDE10AKDM4E | |
| SCHEMBL15459494 | 0.77 | JAK2 (0.43) | JAK2JAK3PTK2PDE10AKDM4E | |
| SCHEMBL24857423 | 0.77 | KDM4E (0.35) | JAK2JAK3PTK2PDE10AKDM4E | |
| SCHEMBL10271981 | 0.77 | PDE10A (0.51) | JAK2JAK3PTK2PDE10AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019521-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | Blueray Therapeutics (Shanghai) Co., Ltd (CN) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021032004-A9 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | 上海青煜医药科技有限公司 | 2021-03-25 | — | — | WO | disclosed |
| WO-2021032004-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | 上海青煜医药科技有限公司 | 2021-02-25 | — | — | WO | disclosed |
| US-20180179209-A1 | JAK INHIBITORS | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2018-06-28 | — | — | US | disclosed |
| US-20180179209-A1 | JAK INHIBITORS | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2018-06-28 | — | — | US | disclosed |
| US-9994590-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170037060-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2017-02-09 | — | — | US | disclosed |
| US-9505751-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-14 | — | — | US | disclosed |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150322090-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-02 | — | — | US | disclosed |
| US-20140221377-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL MYERS SQUIBB CO (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140038939-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8580812-B2 | Heteroaryl amide analogues as P2X7 antagonists | H. LUNDBECK A/S (DK) | 2013-11-12 | — | — | US | disclosed |
| US-20130131064-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-23 | — | — | US | disclosed |
| US-20100266509-A1 | HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS | H. Lindbeck A/S (DK) | 2010-10-21 | — | — | US | disclosed |
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| WO-2007034252-A1 | AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIQUIDS | SANOFI-AVENTIS (FR) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322090-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | JAK2 298/4885JAK3 1229/4885PTK2 3227/4885 |
| US-20140221377-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | JAK2 3535/4885JAK3 3877/4885PTK2 3244/4885 |
| US-20140038939-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885PTK2 312/4885 |
| US-20130131064-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | JAK2 3535/4885JAK3 3877/4885PTK2 3244/4885 |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | JAK2 3535/4885JAK3 3877/4885PTK2 3244/4885 |
| US-20180179209-A1 | JAK INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885PTK2 315/4885 |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | JAK2 3535/4885JAK3 3877/4885PTK2 3244/4885 |
| US-20170037060-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | JAK2 298/4885JAK3 1229/4885PTK2 3227/4885 |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | JAK2 3535/4885JAK3 3877/4885PTK2 3244/4885 |
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | CCR3, CCR1, CCR4 | JAK2 972/4885JAK3 652/4885PTK2 2720/4885 |
| US-20100266509-A1 | HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS | P2RX7, P2RX3, P2RX2 | JAK2 2312/4885JAK3 3779/4885PTK2 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.